Continuing Education Credit for this activity is no longer available.
This course can be taken for informational purposes or for Continuing Education (CE) credit.
Continuing Education Credits (CE) released: 11/01/2020; Valid for credit through: 11/01/2021
For users wishing to have confirmation that they have completed this course, they may choose to receive a Certificate of Completion which comes with no CE credits.
The target audience for this course consists of a national audience of healthcare providers, including physicians, pharmacists, and nurses.
This online web course will educate a national audience of healthcare providers (physicians, pharmacists, nurses, and others) about the reduction of hypoglycemic events in Type 2 diabetes.
Participants must pass the post-test with a score of 70% or higher and complete an evaluation form to receive a certificate of completion or CE credit. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available.
NOTE: If you are seeking continuing education credit for a specialty not listed on this page, it is your responsibility to contact your licensing/certification board to determine eligibility for your licensing/certification requirement.
No commercial support was received for this educational activity.
No in-kind commercial support was received for this educational activity.
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content of CME disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1--6.2, 6.5).
All individuals in a position to control the content of CE/CME are listed below and had no relevant financial relationship to disclose.
|First Name||Last Name||Disclosure|
|Blia||Xiong||Nothing to disclose|
|Sophia||Ni||Nothing to disclose|
|Victoria||Wilson||Nothing to disclose|
|Mary||Ghods||Nothing to disclose|
|Elaine||Frost||Nothing to disclose|
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the US Food and Drug Administration (FDA). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for physicians. Learners should claim only the credit commensurate with the extent of their participation in the activity.
Amedco LLC designates this enduring material for a maximum of 1 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity. UAN(s): JA4008163-9999-20-102-H04-P, JA4008163-9999-20-102-H04-T
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.
Amedco LLC designates this enduring material for a maximum of 1 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.
To access the course, users will need a computer with an Internet connection, and:
An HTML5 capable browser is required for video playback. Occasionally, other additional software may be required such as Microsoft PowerPoint or Adobe Acrobat Reader. Viewing on a desktop, laptop, or tablet is recommended.
This is a responsive course. Parts of the course may display differently across various devices and screen resolutions. Scrolling may be required in some instances.
Users are required to view the entire course before getting access to the post-test. To receive your certificate for CE credit or certificate of completion, you must complete the post-test and receive a score of 70 percent or better and complete an evaluation form.
For questions about content or about technical issues, you may contact FDA:
(855) 543-3784, or